The pharmacokinetics of high dose cyclophosphamide and high dose etoposide

[1]  D. Cunningham,et al.  Etoposide: A pharmacokinetic profile including an assessment of bioavailability , 1986, Medical oncology and tumor pharmacotherapy.

[2]  D. Thomas,et al.  High-dose etoposide in the treatment of relapsed primary brain tumors. , 1985, Cancer treatment reports.

[3]  R. Wittes,et al.  Etoposide (VP-16-213). Current status of an active anticancer drug. , 1985, The New England journal of medicine.

[4]  S. Jagannath,et al.  High‐dose chemotherapy with autologous bone marrow transplantation , 1984, Cancer.

[5]  Etoposide infusions for treatment of metastatic lung cancer. , 1984, Cancer treatment reports.

[6]  G R Wilkinson,et al.  Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. , 1984, Cancer research.

[7]  J. Hainsworth,et al.  High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Mcelwain,et al.  HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.

[9]  H. Prentice,et al.  Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. , 1981, Cancer treatment reports.

[10]  M. D’Incalci,et al.  High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma. , 1981, Journal of chromatography.

[11]  M. D’Incalci,et al.  Decreased half life of cyclophosphamide in patients under continual treatment. , 1979, European journal of cancer.